Eledon Pharmaceuticals, Inc. (ELDN) Presents at Guggenheim Securities 2nd Annual Healthcare Innovation Conference Transcript

Eledon presented 12‑month Phase II BESTOW data for tegoprubart, an anti‑CD40‑ligand antibody aimed to replace tacrolimus in transplantation: in a ~120‑patient randomized study tegoprubart missed the trial’s pre‑specified superiority primary (by ~3 eGFR points after tacrolimus outperformed historical expectations, mean eGFR ~66) but met the standard non‑inferiority composite and showed consistently higher eGFRs in multiple subgroups and clinically meaningful safety advantages (notably far fewer tacrolimus‑associated nephrotoxicity signals, new‑onset diabetes, hypertension, tremors and less delayed graft function). Management said the data generated strong clinician enthusiasm, plans a single Phase III kidney study with 12‑month non‑inferiority endpoints and is engaging the FDA on use of the iBox surrogate; parallel programs include an investigator‑led islet‑cell program (promising early results) and positioning in xenotransplant regimens. Eledon had ~$90m cash at end‑September, is raising additional capital to extend runway to Q1 2027, and near‑term catalysts are End‑of‑Phase‑II regulatory meetings, Phase III design/launch, and clarity on registrational paths for islet and xeno indications.

Analysis

Eledon presented 12‑month Phase II BESTOW results for tegoprubart in ~120 randomized de novo kidney transplant patients (≈60 per arm); the study missed its pre‑specified superiority primary by ~3 eGFR points after tacrolimus outperformed historical expectations (mean eGFR ≈66 on tacrolimus versus the mid‑50s used for powering). The trial nevertheless met the conventional 12‑month non‑inferiority composite for patient/graft survival and biopsy‑proven rejection despite not being powered for that regulatory endpoint.

Tegoprubart showed pronounced safety advantages at 12 months versus tacrolimus, with materially lower signals for new‑onset diabetes, hypertension, neurological toxicities (tremors) and reduced delayed graft function; subgroup analyses reported higher mean eGFRs in living‑donor and high‑KDPI cohorts with deltas up to ~10 points and a continuous KDPI analysis reaching statistical significance. Clinician feedback at ASN was strongly positive on safety, which management positions as the principal commercial differentiator.

Management plans a single Phase III kidney study using a 12‑month non‑inferiority endpoint and is engaging the FDA on incorporation of the iBox surrogate as a potential co‑primary; parallel opportunities include an investigator‑led islet‑cell program (5 of 6 early patients off insulin) and xenotransplant regimens. Corporate cash was reported at ~$90m as of September with an active raise intended to extend runway to Q1 2027, making end‑of‑Phase‑II meetings, Phase III design/launch and islet/xeno regulatory clarity the next material catalysts.

Key Decisions for Investors

• Given the missed superiority primary but clear non‑inferiority and meaningful safety differentiation, consider holding or selectively accumulating on near‑term weakness while sizing exposure for Phase III execution risk
• Monitor three near‑term catalysts closely—end‑of‑Phase‑II FDA discussions (iBox guidance), Phase III design and launch timing, and islet‑cell/xeno readouts—and increase exposure only after favorable regulatory alignment or clear Phase III design de‑risking
• Manage downside with position sizing or hedges because approval and commercial outcomes hinge on a single pivotal Phase III and an ongoing financing (cash runway to Q1 2027), and use subgroup/KDPI signals to assess potential market segmentation